Abstract: The present invention generally relates to sensitizer compounds and their use to sensitize cancer and/or pre-cancerous cells of certain cancers to treatment with certain resistance-prone therapeutics used in cancer therapy. In embodiments, the conjugates of particular esters or amides of Near Infrared Dyes, are used as sensitizers to avoid or overcome therapeutic resistance once formed. In embodiments, the sensitizers include conjugates with Cisplatin, Simvastatin, Artemisinin, platin-based compounds or statins. In embodiments, the resistance prone cancer therapeutics include cisplatin, gemcitabine, doxorubicin, paclitaxel, docetaxel, and platin-based compounds. These may be administered in combination with the sensitizer, or the sensitizer itself may comprise an therapeutic-derived moiety conjugated to the sensitizer, for example as is the case for dye-CIS conjugated sensitizers. Alternatively, the sensitizer may be co-administered with one or more therapeutic.

Abstract: The present invention generally relates to sensitizer compounds and their use in combination with Tyrosine Kinase Inhibitors (TKIs) for sensitizing tumor, cancer or pre-cancerous cells to TKI treatment. In particular, the present invention relates to administration regimes that combine TKIs such as Gefitinib or Icotinib with TKI-sensitizing DZ1 esters and amides conjugated to statin or platin-based drugs, or to Artemisinin, including, without limitation: DZ1-Simvastatin amide, DZ1-Simvastatin ester, DZ1-Cisplatin ester, and DZ1-Cisplatin amide, DZ1-Artemisinin ester, and DZ1-Artemisinin amide. Furthermore, the present invention relates to improved TKI treatment of cancers by sensitizing tumor, cancer or pre-cancerous cells, in particular cancers that develop TKI resistance, including e.g. lung cancer and pancreatic cancer.

Abstract: The present invention generally relates to sensitizer compounds and their use in combination with Tyrosine Kinase Inhibitors (TKIs) for sensitizing tumor, cancer or pre-cancerous cells to TKI treatment. In particular, the present invention relates to administration regimes that combine TKIs such as Gefitinib or Icotinib with TKI-sensitizing DZ1 esters and amides conjugated to statin or platin-based drugs, or to Artemisinin, including, without limitation: DZ1-Simvastatin amide, DZ1-Simvastatin ester, DZ1-Cisplatin ester, and DZ1-Cisplatin amide, DZ1-Artemisinin ester, and DZ1-Artemisinin amide. Furthermore, the present invention relates to improved TKI treatment of cancers by sensitizing tumor, cancer or pre-cancerous cells, in particular cancers that develop TKI resistance, including e.g. lung cancer and pancreatic cancer.

Abstract: A video processing method and apparatus, an electronic device and a storage medium are provided in the present disclosure. In the video processing method provided in the present disclosure, a target frame image of a target video is fixed in response to a triggering instruction, and a target object in the target frame image is removed, then a padding operation is performed on a target area in the target frame image so as to generate and display a padding frame image. Thus, a special effect that the target object disappears from the target video can be realized, thereby providing visual special effects of more personalized and better visual perception for a user in a video application.

Abstract: The present invention discloses a control method, system, electronic device and readable storage medium for a capsule endoscope. The method includes: providing a working apparatus, comprising a capsule endoscope, and an external data recorder for cooperating with and controlling the capsule endoscope; monitoring the received ambient power by the external data recorder before wireless transmission of the capsule endoscope or during an intermittence between two transmissions, and/or monitoring the output power of the capsule endoscope by the external data recorder as data is transmitted during wireless transmission; adjusting the operating state of the working apparatus according to the ambient power and/or output power.

Abstract: The present invention discloses a control method, system, electronic device and readable storage medium for a capsule endoscope. The method includes: providing a working apparatus, comprising a capsule endoscope, and an external data recorder for cooperating with and controlling the capsule endoscope; monitoring the received ambient power by the external data recorder before wireless transmission of the capsule endoscope or during an intermittence between two transmissions, and/or monitoring the output power of the capsule endoscope by the external data recorder as data is transmitted during wireless transmission; adjusting the operating state of the working apparatus according to the ambient power and/or output power.

Abstract: The present invention discloses a capsule endoscope system, an automatic frame rate adjustment method thereof and a computer readable storage medium. The automatic frame rate adjustment method includes: receiving a first acceleration information ac(t) sensed by a first acceleration sensor in a capsule endoscope; receiving a second acceleration information am(t) sensed by a second acceleration sensor in an external device; calculating and comparing the first acceleration information ac(t) and the second acceleration information am(t) to obtain the relative motion amplitude statem(t) between the capsule endoscope and the external device; adjusting the frame rate of the capsule endoscope according to the relative motion amplitude statem(t), where, the larger the relative motion amplitude statem(t), the larger the frame rate F0(t).

Abstract: The present invention discloses a capsule endoscope system, an automatic frame rate adjustment method thereof and a computer readable storage medium. The automatic frame rate adjustment method includes: receiving a first acceleration information ac(t) sensed by a first acceleration sensor in a capsule endoscope; receiving a second acceleration information am(t) sensed by a second acceleration sensor in an external device; calculating and comparing the first acceleration information ac(t) and the second acceleration information am(t) to obtain the relative motion amplitude statem(t) between the capsule endoscope and the external device; adjusting the frame rate of the capsule endoscope according to the relative motion amplitude statem(t), where, the larger the relative motion amplitude statem(t), the larger the frame rate F0(t).

Abstract: The present invention generally relates to sensitizer compounds and their use in combination with Tyrosine Kinase Inhibitors (TKIs) for sensitizing tumor, cancer or pre-cancerous cells to TKI treatment. In particular, the present invention relates to administration regimes that combine TKIs such as Gefitinib or Icotinib with TKI-sensitizing DZ1 esters and amides conjugated to statin or platin-based drugs, or to Artemisinin, including, without limitation: DZ1-Simvastatin amide, DZ1-Simvastatin ester, DZ1-Cisplatin ester, and DZ1-Cisplatin amide, DZ1-Artemisinin ester, and DZ1-Artemisinin amide. Furthermore, the present invention relates to improved TKI treatment of cancers by sensitizing tumor, cancer or pre-cancerous cells, in particular cancers that develop TKI resistance, including e.g. lung cancer and pancreatic cancer.

Abstract: The present invention generally relates to sensitizer compounds and their use to sensitize cancer and/or pre-cancerous cells of certain cancers to treatment with certain resistance-prone therapeutics used in cancer therapy. In embodiments, the conjugates of particular esters or amides of Near Infrared Dyes, are used as sensitizers to avoid or overcome therapeutic resistance once formed. In embodiments, the sensitizers include conjugates with Cisplatin, Simvastatin, Artemisinin, platin-based compounds or statins. In embodiments, the resistance prone cancer therapeutics include cisplatin, gemcitabine, doxorubicin, paclitaxel, docetaxel, and platin-based compounds. These may be administered in combination with the sensitizer, or the sensitizer itself may comprise an therapeutic-derived moiety conjugated to the sensitizer, for example as is the case for dye-CIS conjugated sensitizers. Alternatively, the sensitizer may be co-administered with one or more therapeutic.